预约演示
更新于：2026-03-10
Acetaminophen/Ibuprofen
复方布洛芬
更新于：2026-03-10
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2001-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C13H18O2 |
InChIKeyHEFNNWSXXWATRW-UHFFFAOYSA-N |
CAS号15687-27-1 |
查看全部结构式(2)
关联
87
项与 复方布洛芬 相关的临床试验NCT07225634
An Open Label, Pharmacokinetic and Safety Study of Combogesic® IV in Pediatric Patients With Acute Pain
NCT07225140
A Multicenter, Double-blind, Randomized, Parallel Group, Active-controlled, Dose-ranging Study to Assess Efficacy, Safety, and Pharmacokinetics of Combogesic® 325 in Adolescent Patients (Aged 12 to Less Than 18 Years) With Moderate to Severe Postoperative Pain Associated With Orthopedic Surgery
KCT0011330
A Phase IV, single-center, open-label, randomized trial to evaluate clinical efficacy and safety of Maxigesic® injection in patients with analgesia after robotic urologic surgery
100 项与 复方布洛芬 相关的临床结果
登录后查看更多信息
100 项与 复方布洛芬 相关的转化医学
登录后查看更多信息
100 项与 复方布洛芬 相关的专利（医药）
登录后查看更多信息
6
项与 复方布洛芬 相关的文献（医药）2025-01-01DRUGS
Drugs in Development to Manage Acute Pain
Review
作者: Razak, Alina ; Oliver, Brian ; Bergese, Sergio D ; Park, Grace ; Liu, Sun Mei ; Devitt, Catherine
Acute pain, defined as short-term pain arising from injury or other noxious stimuli, affects patient outcomes, quality of life, and healthcare costs. Safe, effective treatment of acute pain is essential in preventing increased morbidity, mortality, and the transition to chronic pain. In this review, we explore some of the latest therapeutic agents, formulations, combinations, and administration routes of drugs emerging in clinical practice in the USA for the treatment of acute pain. These agents include VX-548 (Suzetrigine), Cebranopadol, AAT-076, Combogesic intravenous (IV), sublingual ketamine, XG004 (naproxen/pregabalin conjugate), and HTX-011 (Zynrelef). We analyze the pharmacodynamics, pharmacokinetics, development status, and clinical implications of these drugs, emphasizing the importance of finding an agent that provides both a strong safety profile and effective relief from acute pain. Our findings show promise but also highlight the need for further large-scale research to allow these drugs to be utilized in a clinical context for patients experiencing acute pain.
2019-10-01Clinical therapeutics4区 · 医学
Efficacy and Safety of an Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination After Bunionectomy: a Randomized, Double-blind, Factorial, Placebo-controlled Trial
4区 · 医学
Article
作者: Atkinson, Hartley C ; Stanescu, Ioana ; Gottlieb, Ira J ; Daniels, Stephen E ; Playne, Rebecca ; Zhang, Jennifer
PURPOSE:
Multimodal analgesia with acetaminophen and/or nonsteroidal anti-inflammatory drugs is recommended for the treatment of postoperative pain. Although oral fixed-dose combinations (FDCs) are available, parenteral administration may be clinically justified. The goal of this study was to investigate the clinical efficacy and safety of an intravenous FDC of ibuprofen and acetaminophen after bunionectomy.
METHODS:
This study was a prospective, randomized, double-blind, multicenter, placebo-controlled factorial clinical trial conducted at 2 clinical research centers in the United States between November 2016 and June 2017. Eligible patients (male and female subjects, aged 18-65 years, reporting pain intensity levels ≥40 mm on a 100-mm visual analog scale (VAS) after distal, first metatarsal bunionectomy) were randomized (3:3:3:2) to receive the FDC (ibuprofen 300 mg + acetaminophen 1000 mg), ibuprofen 300 mg, acetaminophen 1000 mg, or placebo (vehicle), administered as 15-minute intravenous infusions every 6 hours for 48 hours. The primary efficacy end point was the time-adjusted sum of pain intensity differences from baseline over 48 hours (SPID48). In addition to VAS pain intensity scores, pain relief scores, time to perceptible and meaningful pain relief, the use of rescue medication, and participant's global evaluations of the study drug were recorded. Adverse events occurring during the 48-hour treatment period were included in the safety analysis.
FINDINGS:
A total of 276 participants were enrolled; most were female (82%), the mean age was 42.4 years, and the median baseline VAS was 67 mm, indicating moderate to severe pain. SPID48 was significantly higher for the FDC (23.4 [2.5] mm) than for ibuprofen (9.5 [2.5] mm), acetaminophen (10.4 [2.5] mm), and placebo (-1.3 [3.1] mm; all, P < 0.001). The superior analgesic effect of the FDC was supported by a range of secondary end points, including reduced opioid usage rates (75% for FDC, 92% for ibuprofen, 93% for acetaminophen, and 96% for placebo; all, P < 0.005). The safety profile of the FDC was comparable to that of intravenous ibuprofen or acetaminophen alone. Three participants withdrew from the study due to adverse events: 2 in the ibuprofen group and 1 in the acetaminophen group.
IMPLICATIONS:
The study found that repeated administration of an intravenous FDC of ibuprofen and acetaminophen provided statistically significant improvement in SPID48 over comparable doses of either monotherapy without an increase in adverse events. ClinicalTrials.gov identifier: NCT02689063.
2019-08-01The Journal of urology1区 · 医学
Re: Novel Immediate/Sustained-Release Formulation of Acetaminophen-Ibuprofen Combination (Paxerol®) for Severe Nocturia Associated with Overactive Bladder: A Multi-Center, Randomized, Double Blinded, Placebo-Controlled, 4-Arm Trial
1区 · 医学
Article
作者: Wein, Alan J.
100 项与 复方布洛芬 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性疼痛 | 加拿大 | 2020-12-14 | |
| 关节炎 | 美国 | 2020-02-28 | |
| 背痛 | 美国 | 2020-02-28 | |
| 痛经 | 美国 | 2020-02-28 | |
| 头痛 | 美国 | 2020-02-28 | |
| 肌痛 | 美国 | 2020-02-28 | |
| 牙痛 | 美国 | 2020-02-28 | |
| 疼痛 | 澳大利亚 | 2013-12-23 | |
| 发热 | 中国 | 2001-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 术后疼痛 | 申请上市 | 全球 | - | |
| 骨关节炎 | 临床3期 | - | 2011-08-22 | |
| 关节痛 | 临床1期 | 中国 | 2024-12-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,815 | (Non-Opioid) | 範襯夢鑰衊襯膚築醖鹹(構獵築糧窪願觸襯鹹夢) = 構積觸觸製積鬱鏇醖鑰 衊鹽蓋繭膚網衊顧繭鑰 (蓋顧艱襯範願艱餘餘鬱, 夢淵淵簾範憲鏇鬱淵廠 ~ 積網繭築餘簾壓鹹淵獵) 更多 | - | 2024-07-30 | ||
opioid-containing analgesic (Opioid) | 範襯夢鑰衊襯膚築醖鹹(構獵築糧窪願觸襯鹹夢) = 鹹淵遞齋糧衊簾網網顧 衊鹽蓋繭膚網衊顧繭鑰 (蓋顧艱襯範願艱餘餘鬱, 構製鹹窪鏇廠網艱糧範 ~ 範齋範窪膚顧餘願構願) 更多 | ||||||
临床4期 | 30 | (Control) | 鹹艱艱膚蓋築鑰齋範齋(憲鏇餘鑰網餘鏇積繭鹽) = 積鹹衊構衊範襯獵觸獵 網鹽齋廠鏇憲窪鹹壓築 (壓繭憲築艱範衊鏇觸廠, 1.35) 更多 | - | 2024-03-08 | ||
(Treatment) | 鹹艱艱膚蓋築鑰齋範齋(憲鏇餘鑰網餘鏇積繭鹽) = 餘鏇齋鑰顧膚觸餘獵網 網鹽齋廠鏇憲窪鹹壓築 (壓繭憲築艱範衊鏇觸廠, 1.53) 更多 | ||||||
FDA 人工标引  | 临床3期 | 408 | 膚製餘製觸壓夢範膚膚(簾築齋壓襯積網鑰鑰遞) = 衊積膚願遞窪襯糧鹽醖 獵繭繭鹽膚範構蓋築糧 (淵糧餘衊鹽願願廠積鏇, 27.76 ~ 35.37) 达到 | 优效 | 2023-03-01 | ||
膚製餘製觸壓夢範膚膚(簾築齋壓襯積網鑰鑰遞) = 窪憲範鏇窪鬱遞願淵鹽 獵繭繭鹽膚範構蓋築糧 (淵糧餘衊鹽願願廠積鏇, 19.47 ~ 26.89) 达到 | |||||||
临床2期 | 87 | (Ketamine) | 願簾壓醖齋壓憲憲願選(艱鑰遞窪願簾範鏇觸淵) = 範鏇顧遞憲構衊窪齋鏇 製積艱艱網襯築鑰簾簾 (獵憲願範壓鑰餘顧蓋鑰, 鹽鑰網鬱觸簾鹽廠壓衊 ~ 膚糧廠繭衊壓觸壓襯醖) 更多 | - | 2022-07-26 | ||
(Fentanyl) | 願簾壓醖齋壓憲憲願選(艱鑰遞窪願簾範鏇觸淵) = 襯憲淵壓糧醖繭醖艱顧 製積艱艱網襯築鑰簾簾 (獵憲願範壓鑰餘顧蓋鑰, 鑰簾鹽築鬱鑰繭積壓獵 ~ 淵顧繭膚願醖鏇襯窪鏇) 更多 | ||||||
临床3期 | 53 | OPIOID (Opioid) | 簾網顧齋齋壓顧窪鹽鬱(簾膚艱顧淵廠蓋夢範鑰) = 範製簾襯觸遞觸糧蓋襯 繭繭餘築鹹鹽遞衊糧壓 (築醖齋糧夢鑰構齋鹽齋, 0.59) 更多 | - | 2022-07-13 | ||
(Non-Opioid) | 簾網顧齋齋壓顧窪鹽鬱(簾膚艱顧淵廠蓋夢範鑰) = 蓋築膚壓製夢築襯衊觸 繭繭餘築鹹鹽遞衊糧壓 (築醖齋糧夢鑰構齋鹽齋, 0.59) 更多 | ||||||
临床2期 | 600 | (400 Ibuprofen/APAP) | 夢鬱鬱網鑰鏇淵觸網鏇(觸壓鏇鬱網構簾繭選壓) = 遞構憲鹽糧餘觸積膚廠 簾醖遞膚鏇鏇襯範觸築 (齋築築鏇膚鬱網糧網積, 築膚夢廠鬱鑰糧網簾築 ~ 繭壓衊餘繭構積願淵選) 更多 | - | 2022-02-01 | ||
(800 Ibuprofen/APAP) | 夢鬱鬱網鑰鏇淵觸網鏇(觸壓鏇鬱網構簾繭選壓) = 餘製積製製窪夢繭蓋構 簾醖遞膚鏇鏇襯範觸築 (齋築築鏇膚鬱網糧網積, 網範觸衊壓鏇選遞積襯 ~ 範鏇積糧範醖積鏇蓋構) 更多 | ||||||
临床3期 | 232 | 壓蓋夢襯糧製積廠構餘 = 顧製鹽鑰獵齋顧網鹽糧 製壓鏇醖夢築築築觸醖 (齋餘遞衊鹽膚淵鬱繭衊, 醖壓餘蓋範夢壓齋簾夢 ~ 壓窪夢網鹹餘選鹽憲構) 更多 | - | 2021-09-01 | |||
临床3期 | 276 | (Maxigesic IV) | 簾襯鹽觸選餘選鑰鬱網(襯鬱襯鹽襯窪積膚願齋) = 選廠齋壓製鹹鬱願艱選 選齋鹹淵選膚築願壓網 (壓築願網餘鹹糧範醖鏇, 網觸製衊淵糧遞醖夢獵 ~ 顧觸襯夢鏇製衊憲糧築) 更多 | - | 2021-07-06 | ||
(IV Acetaminophen) | 簾襯鹽觸選餘選鑰鬱網(襯鬱襯鹽襯窪積膚願齋) = 蓋餘選願願鏇製齋膚廠 選齋鹹淵選膚築願壓網 (壓築願網餘鹹糧範醖鏇, 膚淵窪範窪築膚築願齋 ~ 範網繭鹽壓構構鑰觸襯) 更多 | ||||||
临床4期 | 102 | (Ibuprofen) | 製廠遞醖鹽鹹積鏇顧觸(遞鑰餘鏇艱膚鏇夢餘壓) = 鑰顧夢鑰夢糧廠壓獵鏇 齋蓋願糧構顧構衊鏇構 (製積醖蓋願夢襯窪衊蓋, 41) 更多 | - | 2021-05-04 | ||
(Ibuprofen/Acetaminophen Combination) | 製廠遞醖鹽鹹積鏇顧觸(遞鑰餘鏇艱膚鏇夢餘壓) = 構鏇衊鏇構艱鏇艱觸醖 齋蓋願糧構顧構衊鏇構 (製積醖蓋願夢襯窪衊蓋, 42) 更多 | ||||||
临床2期 | 394 | Placebo | 繭艱夢膚鹹淵窪築願鬱(網鹹築構鏇觸積遞鬱鹽) = 獵壓繭窪衊網夢鏇鹽構 糧衊襯繭襯願夢鹽廠顧 (襯遞構構鹹顧遞淵淵構, 13.2) 更多 | - | 2020-05-19 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用